Friederike Schlurmann
Brest, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial.
Journal: European urology oncology
Published: September 09, 2024
Enzalutamide, in biologically relapsed prostate cancer
Journal: Bulletin du cancer
Published: August 16, 2024
The effect of tumor downsizing on surgical complexity during nephrectomy after immune checkpoint inhibitors for metastatic renal cell carcinoma.
Journal: World journal of urology
Published: April 21, 2024
Nivolumab in patients with advanced renal cell carcinoma in France: interim results of the observational, real-world WITNESS study.
Journal: ESMO open
Published: January 31, 2024
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.
Journal: The Lancet. Oncology
Published: June 02, 2023
New drugs approval: Lutetium-PSMA in metastatic castration-resistant prostate cancer
Journal: Bulletin du cancer
Published: January 24, 2023
Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer.
Journal: NEJM evidence
Published: September 01, 2022
Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma.
Journal: European urology oncology
Published: March 23, 2022
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Journal: Lancet (London, England)
Published: January 19, 2022
Cabozantinib-nivolumab sequence in metastatic renal cell carcinoma: The CABIR study.
Journal: International journal of cancer
Published: January 14, 2022
Feasibility Study and Preliminary Results of Prognostic Value of Bone SPECT-CT Quantitative Indices for the Response Assessment of Bone Metastatic Prostate Carcinoma to Abiraterone.
Journal: Frontiers in medicine
Published: May 14, 2019
Management of non-metastatic castrate-resistant prostate cancer: A systematic review.
Journal: Cancer treatment reviews
Published: April 11, 2018
Last Updated: 09/26/2026